Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany

Summary Omalizumab is a humanized monoclonal anti-immunoglobulin E (IgE) antibody indicated in Europe for the treatment of uncontrolled severe persistent allergic (IgE-mediated) asthma despite optimal therapy with inhaled corticosteroids and long-acting β2 agonists. Between 2005 and 2007 280 patients (58% female, mean age 44 ± 16 yrs., 46% on oral corticosteroids, median serum IgE level 235 IU/ml) who met the EU criteria for add-on therapy with anti-IgE were treated prospectively with omalizumab by 134 physicians as part of a post-marketing surveillance trial and were followed-up for 6 months. The median follow-up time was 195 days, the patients were treated with a median dose of 450 mg omalizumab every 4 weeks. After 6 months there was a marked effect of omalizumab treatment on daily (−76%) and nocturnal symptoms (−84%), exacerbations (−82%), unscheduled health care contacts (−81%), hospitalizations (−78%) and quality of life (Mini-AQLQ: score increase from 2.9 to 4.5). Overall, efficacy of omalizumab was rated as excellent or good by the majority of physicians (82%) and patients (86%). In 19 patients (7%) omalizumab-related adverse events were recorded. This post-marketing surveillance trial confirms the marked and clinically relevant effect of omalizumab on asthma symptoms and level of asthma control in the majority of patients with severe persistent allergic (IgE-mediated) asthma in a real-life situation.